Feng Chen1, Jiefu Yang2, Yingying Li2, Hua Wang3. 1. Department of Cardiology, Cardiovascular Institute and Fuwai Hospital, National Center for Cardiovascular Diseases China, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China. 2. Department of Cardiology, Beijing Hospital, National Center of Gerontology, 100730, Beijing, China. 3. Department of Cardiology, Beijing Hospital, National Center of Gerontology, 100730, Beijing, China. Electronic address: wh74220@aliyun.com.
Abstract
OBJECTIVE: We Sought to identify circulating miRNAs suitable for HF diagnosis. METHODS: In this study, a genome-wide plasma miRNA microarray was performed in 13 HF patients and 3 controls. The expression levels of selected differentially expressed, upregulated miRNAs (miR-3135b, miR-3908 and miR-5571-5p) were validated with quantitative real-time PCR (qRT-PCR) assays in an independent cohort of 33 HF patients and 20 controls. RESULTS: Of all the miRNAs analyzed, miR-3135b (P<0.001), miR-3908 (P<0.001), and miR-5571-5p (P<0.001) were found to have significantly different expression levels in HF compared to controls. The Receiver operating characteristic (ROC) curves for miR-3135b, miR-3908, and miR-5571-5p revealed area under the curve (AUC) values of 1.00, 0.86, and 0.94, respectively. More importantly, miR-3135b and miR-3908 were able to discriminate heart failure with reduced ejection fraction (HFrEF) from heart failure with preserved ejection fraction (HFpEF) (P<0.05). The miR-5571-5p plasma level was significantly associated with NYHA class (P<0.001). CONCLUSION: This study demonstrated for the first time that some specific microRNAs (miR-3135b, miR-3908, and miR-5571-5p) are useful biomarkers for HF and for differentiating HFrEF from HFpEF.
OBJECTIVE: We Sought to identify circulating miRNAs suitable for HF diagnosis. METHODS: In this study, a genome-wide plasma miRNA microarray was performed in 13 HF patients and 3 controls. The expression levels of selected differentially expressed, upregulated miRNAs (miR-3135b, miR-3908 and miR-5571-5p) were validated with quantitative real-time PCR (qRT-PCR) assays in an independent cohort of 33 HF patients and 20 controls. RESULTS: Of all the miRNAs analyzed, miR-3135b (P<0.001), miR-3908 (P<0.001), and miR-5571-5p (P<0.001) were found to have significantly different expression levels in HF compared to controls. The Receiver operating characteristic (ROC) curves for miR-3135b, miR-3908, and miR-5571-5p revealed area under the curve (AUC) values of 1.00, 0.86, and 0.94, respectively. More importantly, miR-3135b and miR-3908 were able to discriminate heart failure with reduced ejection fraction (HFrEF) from heart failure with preserved ejection fraction (HFpEF) (P<0.05). The miR-5571-5p plasma level was significantly associated with NYHA class (P<0.001). CONCLUSION: This study demonstrated for the first time that some specific microRNAs (miR-3135b, miR-3908, and miR-5571-5p) are useful biomarkers for HF and for differentiating HFrEF from HFpEF.
Authors: Brittany M Navarre; Katie L Clouthier; Xuhuai Ji; Anne Taylor; Chad S Weldy; Anne M Dubin; Sushma Reddy Journal: J Cardiovasc Transl Res Date: 2022-09-19 Impact factor: 3.216
Authors: Tereza Nováková; Táňa Macháčková; Jan Novák; Petr Hude; Július Godava; Víta Žampachová; Jan Oppelt; Filip Zlámal; Petr Němec; Helena Bedáňová; Ondřej Slabý; Julie Bienertová-Vašků; Lenka Špinarová; Jan Krejčí Journal: Cells Date: 2019-11-06 Impact factor: 6.600
Authors: Sek Ying Chair; Judy Yuet Wa Chan; Mary Miu Yee Waye; Ting Liu; Bernard Man Hin Law; Wai Tong Chien Journal: Int J Environ Res Public Health Date: 2021-05-31 Impact factor: 3.390